Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiencyEKHART, Corine; MARTIJN KERST, J; RODENHUIS, Sjoerd et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 2, pp 375-379, issn 0344-5704, 5 p.Article

Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesKEIZER, Ron J; HUITEMA, Alwin D. R; SCHELLENS, Jan H. M et al.Clinical pharmacokinetics. 2010, Vol 49, Num 8, pp 493-507, issn 0312-5963, 15 p.Article

Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasmaHUITEMA, Alwin D. R; REINDERS, Cindy; TIBBEN, Matthijs M et al.Journal of chromatography. B, Biomedical sciences and applications. 2001, Vol 757, Num 2, pp 349-357, issn 1387-2273Article

A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometryTER HEINE, Rob; ROSING, Hilde; BEIJNEN, Jos H et al.Clinical chemistry and laboratory medicine. 2010, Vol 48, Num 8, pp 1153-1155, issn 1434-6621, 3 p.Article

Integrated population pharmacokinetic model of both Cyclophosphamide and thiotepa suggesting a mutual drug-drug interactionDE JOUGE, Milly E; HUITEMA, Alwin D. R; RODENHUIS, Sjoerd et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2004, Vol 31, Num 2, pp 135-156, issn 1567-567X, 22 p.Article

Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatographyKAPPELHOFF, Bregt S; ROSING, Hilde; HUITEMA, Alwin D. R et al.Journal of chromatography. B. 2003, Vol 792, Num 2, pp 353-362, issn 1570-0232, 10 p.Article

Optimal Dosing of Miltefosine in Children and Adults with Visceral LeishmaniasisDORLO, Thomas P. C; HUITEMA, Alwin D. R; BEIJNEN, Jos H et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 7, pp 3864-3872, issn 0066-4804, 9 p.Article

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment errorCOEN VAN HASSELT, J. G; SCHELLENS, Jan H. M; BEIJNEN, Jos H et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 913-927, issn 0167-6997, 15 p.Article

Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS)EKHART, Corine; GEBRETENSAE, Abadi; ROSING, Hilde et al.Journal of chromatography. B. 2007, Vol 854, Num 1-2, pp 345-349, issn 1570-0232, 5 p.Article

Flat dosing of carboplatin is justified in adult patients with normal renal functionEKHART, Corine; DE JONGE, Milly E; HUITEMA, Alwin D. R et al.Clinical cancer research. 2006, Vol 12, Num 21, pp 6502-6508, issn 1078-0432, 7 p.Article

Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detectionKERBUSCH, Thomas; JEUKEN, Marie-José; DERRAZ, Jamila et al.Therapeutic drug monitoring. 2000, Vol 22, Num 5, pp 613-620, issn 0163-4356Article

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?EKHART, Corine; RODENHUIS, Sjoerd; SCHELLENS, Jan H. M et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 1, pp 115-122, issn 0344-5704, 8 p.Article

Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapyDE JONGE, Milly E; HUITEMA, Alwin D. R; TUKKER, Annemarie C et al.Clinical cancer research. 2005, Vol 11, Num 1, pp 273-283, issn 1078-0432, 11 p.Article

Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A reviewDE JONGE, Milly E; HUITEMA, Alwin D. R; SCHELLENS, Jan H. M et al.Clinical pharmacokinetics. 2005, Vol 44, Num 2, pp 147-173, issn 0312-5963, 27 p.Article

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepaEKHART, Corine; DOODEMAN, Valerie D; RODENBUIS, Sjoerd et al.British journal of clinical pharmacology. 2009, Vol 67, Num 1, issn 0306-5251, 50-60, 145 [12 p.]Article

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamideEKHART, Corine; DOODEMAN, Valerie D; RODENHUIS, Sjoerd et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 6, pp 515-523, issn 1744-6872, 9 p.Article

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatinEKHART, Corine; RODENHUIS, Sjoerd; SMITS, Paul H. M et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 11, pp 1009-1015, issn 1744-6872, 7 p.Article

A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulamZANDVLIET, Anthe S; SCHELLENS, Jan H. M; COPALU, William et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2006, Vol 33, Num 5, pp 543-570, issn 1567-567X, 28 p.Article

Significant induction of cyclophosphamide and thiotepa metabolism by phenytoinDE JONGE, Milly E; HUITEMA, Alwin D. R; VAN DAM, Selma M et al.Cancer chemotherapy and pharmacology. 2005, Vol 55, Num 5, pp 507-510, issn 0344-5704, 4 p.Article

Photophobia in a patient with high indinavir plasma concentrationsHUITEMA, Alwin D. R; KUIPER, Rob A. J; MEENHORST, Pieter L et al.Therapeutic drug monitoring. 2003, Vol 25, Num 6, pp 735-737, issn 0163-4356, 3 p.Article

Population pharmacokinetics of thio TEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapyHUITEMA, Alwin D. R; MATHOT, Ron A. A; TIBBEN, Matthijs M et al.British journal of clinical pharmacology. 2001, Vol 51, Num 1, pp 61-70, issn 0306-5251Article

A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamideHUITEMA, Alwin D. R; MATHOT, Ron A. A; TIBBEN, Matthijs M et al.Journal of pharmacokinetics and pharmacodynamics (Print). 2001, Vol 28, Num 3, pp 211-230, issn 1567-567XArticle

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer CareLANKHEET, Nienke A. G; KNAPEN, Lotte M; SCHELLENS, Jan H. M et al.Therapeutic drug monitoring. 2014, Vol 36, Num 3, pp 326-334, issn 0163-4356, 9 p.Article

Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenzKROMDIJK, Wiete; MULDER, Jan W; ROSING, Hilde et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 5, pp 1211-1216, issn 0305-7453, 6 p.Article

Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumorsJOERGER, Markus; HUITEMA, Alwin D. R; VAN DEN BONGARD, Desiree H. J. G et al.Clinical cancer research. 2006, Vol 12, Num 7, issn 1078-0432, 1951-1953, 2150-2157 [11 p.], 1Article